Natco Pharma share news and announcements
NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹785.15.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹15,534 Cr380th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 14 Aug 2026
- 13.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- 13.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 8.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.08
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 5,69,53550.8% delivered
Natco Pharma analyst meets
77 filed, newest first. Page 1 of 2.
Sep 2026
2 Sep · Analysts
Aug 2026
24 Aug · Analysts
19 Aug · Analysts
16 Aug · Analysts
11 Aug · Analysts
May 2026
21 May · Analysts
Mar 2026
6 Mar · Analysts
Feb 2026
Nov 2025
Sep 2025
4 Sep · Analysts
Aug 2025
6 Aug · Analysts
Jul 2025
23 Jul · Analysts
Jun 2025
12 Jun · Analysts
May 2025
Feb 2025
27 Feb · Analysts
24 Feb · Analysts
10 Feb · Analysts
3 Feb · Analysts
Oct 2024
30 Oct · Analysts
Sep 2024
16 Sep · Analysts
16 Sep · Analysts
6 Sep · Analysts
2 Sep · Analysts
Aug 2024
28 Aug · Analysts
9 Aug · Analysts
Jul 2024
2 Jul · Analysts
Jun 2024
4 Jun · Analysts
May 2024
24 May · Analysts
24 May · Analysts
Apr 2024
18 Apr · Analysts
Mar 2024
2 Mar · Analysts
Feb 2024
23 Feb · Analysts
6 Feb · Analysts
Dec 2023
11 Dec · Analysts
Nov 2023
25 Nov · Analysts
9 Nov · Analysts
Aug 2023
May 2023
23 May · Analysts
Feb 2023
4 Feb · Analysts
Nov 2022
Aug 2022